The Week

Editas Medicine (EDIT) fell 16.41% this week to close at $2.70, while the S&P 500 slipped 0.8%, leaving the stock about 15.61 percentage points behind. The four-session week tracked a sustained slide: Tuesday opened at $3.20, hit a high of $3.215, then faded to $3.03; Wednesday dropped to $2.77; Thursday touched the weekly low of $2.62 before closing at $2.65; Friday edged back to $2.70. Intraweek amplitude was 18.59% on heavier turnover, with average daily volume around 2.56m shares, up roughly 24% from the median. The close sits below both the 20-day moving average of $3.02 and the 60-day average of $2.97.

Key Events

The week’s company news centred on a leadership change. On 8 September Editas appointed Dan Ory as chief medical officer; the next day the company granted Ory 950,000 stock options at an exercise price of $3.03 each, followed by an initial beneficial ownership filing on 10 September. In parallel, Editas disclosed progress on EDIT-401: on 9 September reports said the company plans a first-in-human trial for the CRISPR cholesterol therapy, and on 12 September it said it is targeting 2026 patient dosing for the LDL gene-editing programme. On the filing side, the week’s substantive item was an S-8 form, consistent with the option grant.

Analyst Ratings

Thirteen brokers cover the stock: 7 rate it strong buy, 4 hold, and 2 underweight, with a consensus rating of buy. The consensus target price is $6, about 122.22% above the last close of $2.70. Target estimates are wide apart, from $1 to $15, pointing to divergent views on EDIT-401. Within biotechnology, Editas ranks 79th out of 506 names on analyst rating strength.

The Week Ahead

Macro data dominates the next session. The New York Fed manufacturing index lands on 15 September, with a prior reading of 20.6 and a forecast of 14.75. On 16 September retail sales, retail sales ex-autos, import prices, the NAHB housing market index and EIA crude inventories are all due. For Editas, the key question is whether the company adds execution detail to its 2026 patient-dosing target for LDL gene editing now that the first-in-human trial plan for EDIT-401 is out.

In Short

Editas moved on both management and pipeline this week, and the broker consensus remains constructive, yet the stock fell more than 16% and closed below its moving averages. That gap between analyst targets and market pricing is the tension to watch. The next test is whether the EDIT-401 first-in-human trial and the LDL gene-editing timeline firm up into concrete milestones.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.